Erste Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $53.8M | Sell |
426,561
-121,272
| -22% | -$16M | 0.42% | 50 |
|
|
2026
Q1 | $74.8M | Buy |
547,833
+73,366
| +15% | +$10.3M | 0.69% | 36 |
|
|
2025
Q4 | $59.2M | Buy |
474,467
+27,625
| +6% | +$3.36M | 0.5% | 50 |
|
|
2025
Q3 | $50.3M | Sell |
446,842
-30,299
| -6% | -$3.44M | 0.49% | 55 |
|
|
2025
Q2 | $52.7M | Buy |
477,141
+83,048
| +21% | +$8.84M | 0.44% | 54 |
|
|
2025
Q1 | $44.1M | Buy |
394,093
+2,319
| +0.6% | +$239K | 0.57% | 52 |
|
|
2024
Q4 | $36.9M | Sell |
391,774
-18,055
| -4% | -$1.63M | 0.45% | 61 |
|
|
2024
Q3 | $34.3M | Buy |
409,829
+2,175
| +0.5% | +$166K | 0.41% | 67 |
|
|
2024
Q2 | $28.1M | Buy |
407,654
+2,785
| +0.7% | +$186K | 0.37% | 75 |
|
|
2024
Q1 | $29.6M | Sell |
404,869
-11,333
| -3% | -$871K | 0.4% | 73 |
|
|
2023
Q4 | $33.8M | Buy |
416,202
+26,249
| +7% | +$2.04M | 0.49% | 62 |
|
|
2023
Q3 | $29.4M | Buy |
389,953
+3,865
| +1% | +$297K | 0.51% | 64 |
|
|
2023
Q2 | $29.4M | Sell |
386,088
-83,502
| -18% | -$6.66M | 0.52% | 57 |
|
|
2023
Q1 | $38.2M | Sell |
469,590
-36,100
| -7% | -$2.99M | 0.73% | 40 |
|
|
2022
Q4 | $43.1M | Buy |
505,690
+63,978
| +14% | +$5.07M | 0.91% | 28 |
|
|
2022
Q3 | $27.9M | Buy |
441,712
+14,247
| +3% | +$898K | 0.62% | 46 |
|
|
2022
Q2 | $26.7M | Buy |
427,465
+12,418
| +3% | +$769K | 0.59% | 46 |
|
|
2022
Q1 | $24.8M | Buy |
415,047
+2,959
| +0.7% | +$189K | 0.47% | 63 |
|
|
2021
Q4 | $30.3M | Buy |
412,088
+29,164
| +8% | +$2.01M | 0.55% | 56 |
|
|
2021
Q3 | $27.2M | Buy |
382,924
+11,173
| +3% | +$785K | 0.54% | 58 |
|
|
2021
Q2 | $25.3M | Sell |
371,751
-5,459
| -1% | -$365K | 0.5% | 61 |
|
|
2021
Q1 | $24.7M | Buy |
377,210
+15,390
| +4% | +$992K | 0.6% | 52 |
|
|
2020
Q4 | $20.6M | Buy |
361,820
+10,460
| +3% | +$631K | 0.57% | 49 |
|
|
2020
Q3 | $21.8M | Sell |
351,360
-36,860
| -9% | -$2.56M | 0.74% | 36 |
|
|
2020
Q2 | $29.1M | Buy |
388,220
+74,015
| +24% | +$5.67M | 1.16% | 14 |
|
|
2020
Q1 | $23.7M | Buy |
314,205
+94,495
| +43% | +$6.53M | 1.38% | 13 |
|
|
2019
Q4 | $14.5M | Sell |
219,710
-63,745
| -22% | -$4.15M | 0.64% | 41 |
|
|
2019
Q3 | $17.8M | Buy |
283,455
+1,515
| +0.5% | +$99K | 0.95% | 27 |
|
|
2019
Q2 | $18.9M | Sell |
281,940
-18,500
| -6% | -$1.22M | 1% | 25 |
|
|
2019
Q1 | $19.1M | Buy |
300,440
+148,800
| +98% | +$9.89M | 1.07% | 22 |
|
|
2018
Q4 | $9.54M | Buy |
+151,640
| New | +$10.6M | 0.64% | 33 |
|
Other funds holding GILD
Erste Asset Management's GILD Position: Q2 2026 in Review
Erste Asset Management reduced its Gilead Sciences (GILD) stake by 22% in Q2 2026, selling an estimated $16M and leaving 426,561 shares worth $53.8M. The position accounts for 0.42% of the portfolio, ranked #50.
Erste Asset Management first reported a position in GILD in Q4 2018 and has held it in 31 quarters since. The position peaked at $74.8M in Q1 2026. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Erste Asset Management held 426,561 shares of Gilead Sciences worth $53.8M as of Q2 2026.
- Erste Asset Management sold 121,272 Gilead Sciences shares in Q2 2026, an estimated $16M.
- Gilead Sciences made up 0.42% of Erste Asset Management's portfolio in Q2 2026, its #50 holding.
- Erste Asset Management first reported a position in Gilead Sciences in Q4 2018 and has held it in 31 quarters since.
- Erste Asset Management's Gilead Sciences position peaked at $74.8M in Q1 2026.
- 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.